SUZHOU, China, March 26, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-line HER2-positive GC, with data presented as a LBA oral presentation at the 2025 ESMO Congress. The first NDA was accepted by the NMPA and received priority review status, followed by successful completion of drug registration inspection and GMP compliance inspection, and is on the verge of market launch. Patient enrollment has been completed for two phase III studies in…